MRNS - MRNS Class Action Alert: Robbins LLP Reminds MRNS Stockholders About the Marinus Pharmaceuticals Inc. Securities Fraud Class Action | Benzinga
SAN DIEGO, June 20, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) securities between March 17, 2021 and May 7, 2024. Marinus describes itself as a "commercial-stage company dedicated to the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY® (ganaxolone)."
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
The Allegations: Robbins LLP is Investigating Allegations Marinus Pharmaceuticals, Inc. (MRNS) Misled Investors Regarding the Viability of its Drug Candidate
According to the complaint, defendants failed to disclose that (1) defendants understated the risk of failure to meet the early-stopping criteria in the RAISE trial, and (2) defendants did not disclose that a possible consequence of failing to meet the early stopping criteria in the RAISE trial would be that Marinus would ...